A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
Luis E. Raez*, Edgardo S. Santos, R. Timothy Webb, James Wade, Roger A. Brito, Melissa Karr, Andra Kennah, Barrett H. Childs
Dive into the research topics of 'A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)'. Together they form a unique fingerprint.